Market Cap 6.57B
Revenue (ttm) 221.90M
Net Income (ttm) -535.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -241.44%
Debt to Equity Ratio -1.18
Volume 3,045,300
Avg Vol 2,984,704
Day's Range N/A - N/A
Shares Out 190.19M
Stochastic %K 4%
Beta 1.07
Analysts Strong Sell
Price Target $54.60

Latest News on BBIO

BridgeBio Announces CFO Succession

Mar 17, 2025, 4:01 PM EDT - 15 days ago

BridgeBio Announces CFO Succession


BridgeBio: Strong Start For Attruby

Feb 20, 2025, 1:34 PM EST - 5 weeks ago

BridgeBio: Strong Start For Attruby


Top 4 Health Care Stocks You May Want To Dump In Q1

Jan 21, 2025, 6:06 AM EST - 2 months ago

Top 4 Health Care Stocks You May Want To Dump In Q1

BSX ISRG ITCI


BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval

Jan 15, 2025, 9:30 AM EST - 2 months ago

BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval


BridgeBio: Next Chapter Begins After Attruby Approval

Nov 24, 2024, 3:48 PM EST - 4 months ago

BridgeBio: Next Chapter Begins After Attruby Approval


US FDA approves BridgeBio's drug for rare heart condition

Nov 22, 2024, 7:25 PM EST - 4 months ago

US FDA approves BridgeBio's drug for rare heart condition


BridgeBio to stop development of therapy for genetic disorder

Sep 10, 2024, 5:09 PM EDT - 7 months ago

BridgeBio to stop development of therapy for genetic disorder


BridgeBio Pharma to Participate in September Investor Events

Aug 28, 2024, 7:30 AM EDT - 7 months ago

BridgeBio Pharma to Participate in September Investor Events